Phase II Window Studies: 10 Years of Experience and Counting
- 1 August 2001
- journal article
- editorial
- Published by Wolters Kluwer Health in Journal of Pediatric Hematology/Oncology
- Vol. 23 (6), 334-337
- https://doi.org/10.1097/00043426-200108000-00002
Abstract
No abstract availableThis publication has 27 references indexed in Scilit:
- Presurgical Window of Carboplatin and Surgery and Multidrug Chemotherapy for the Treatment of Newly Diagnosed Metastatic or Unresectable Osteosarcoma: Pediatric Oncology Group TrialJournal of Pediatric Hematology/Oncology, 2001
- Ifosfamide and Etoposide Are Superior to Vincristine and Melphalan for Pediatric Metastatic Rhabdomyosarcoma When Administered With Irradiation and Combination Chemotherapy: A Report From the Intergroup Rhabdomyosarcoma Study GroupJournal of Pediatric Hematology/Oncology, 2001
- Activity of intraarterial carboplatin as a single agent in the treatment of newly diagnosed extremity osteosarcomaMedical and Pediatric Oncology, 1999
- Phase II Window of Idarubicin in Children With Extraocular RetinoblastomaJournal of Clinical Oncology, 1999
- Activity of high-dose cyclophosphamide in the treatment of childhood malignant gliomasMedical and Pediatric Oncology, 1998
- Response of untreated stage IV Wilms' tumor to single dose carboplatin assessed by “up front” window therapyMedical and Pediatric Oncology, 1995
- A phase II evaluation of thiotepa followed by other multiagent chemotherapy regimens in infants and young children with malignant brain tumorsCancer, 1995
- Treatment of osteosarcoma with ifosfamide: Comparison of response in pediatric patients with recurrent disease versus patients previously untreated: A pediatric oncology group studyMedical and Pediatric Oncology, 1995
- Phase II investigational window using carboplatin, iproplatin, ifosfamide, and epirubicin in children with untreated disseminated neuroblastoma: a Pediatric Oncology Group study.Journal of Clinical Oncology, 1994
- Phase II testing of melphalan in children with newly diagnosed rhabdomyosarcoma: a model for anticancer drug development.Journal of Clinical Oncology, 1988